# iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)

> **NCT05413369** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 582 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Insulin glargine/Lixisenatide
- **DRUG:** IDegAsp
- **DRUG:** Metformin
- **DRUG:** SGLT2 inhibitor

## Key facts

- **NCT ID:** NCT05413369
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-07
- **Primary completion:** 2023-10-20
- **Final completion:** 2023-10-20
- **Target enrollment:** 582 (ACTUAL)
- **Last updated:** 2025-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05413369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05413369, "iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05413369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*